Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Monday, March 31, 2014 9:24:10 AM
Q-results out today ...
Burn-rate down to $400k Per Q / Cash untill year End means they have enough time after the 2x Phase 3 data to do a financing at much much higher Price if data is positive . A lottery ticket here that could make you rich .GLTA
Q-Results released today ..
http://finance.yahoo.com/news/adherex-provides-corporate-fiscal-ended-120000833.html
Cash and cash equivalents totaled $1.7 million at December 31, 2013
The two Phase 3 clinical trials studying Sodium Thiosulfate (STS) for prevention of hearing loss in children receiving cisplatin chemotherapy have progressed well. The US based Children Oncology Group (COG) ACCL0431 study completed enrollment in February 2012. Final data is expected to be released by COG during American Society of Clinical Oncology (ASCO) meeting in June 2014.
The enrollment of the European based SIOPEL 6 Study is almost complete, as 96 out of planned 102 patients have been randomized. The first three interim safety analyses were conducted after 20, 40 and 60 patients, and in each case, the Independent Data Monitoring Committee (IDMC) has recommended continuation of the study. An additional interim safety analysis for 80 patients is also expected to be performed shortly. Safety review data from this study have been submitted for presentation at ASCO in June 2014.
"We are encouraged by the recent strong patient participation in SIOPEL 6 and the continued recommendation by the IDMC that the study continue. In the event, that data from COG and SIOPEL show compelling results, Adherex plans to discuss the regulatory filing strategy for a New Drug Application (NDA) with the FDA during the second half of 2014" stated Mr. Rosty Raykov, Chief Executive Officer of Adherex.
Recent FENC News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 09:02:25 PM
- Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/05/2024 10:56:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:48:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:33:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/04/2024 08:05:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 08/27/2024 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 09:51:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:02:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 10:59:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:10:11 PM
- Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 10:05:00 AM
- Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:31:00 PM
- Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director • GlobeNewswire Inc. • 08/05/2024 10:26:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:30:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:21:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:08:11 PM
- Fennec Pharmaceuticals Announces Management Change • GlobeNewswire Inc. • 07/01/2024 10:00:00 AM
- Fennec Announces Results of Annual Meeting • GlobeNewswire Inc. • 06/25/2024 08:35:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 10:21:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:12:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:25 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM